ZHBIO(SZ:300653)2023-10-23 16:00Financial Performance - The company's revenue for Q3 2023 was ¥97,275,956.97, a decrease of 11.44% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥38,493,412.52, down 24.92% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.21, reflecting a 25.00% decline compared to the previous year[5]. - Total operating revenue for the current period is CNY 321,781,527.57, a decrease of 5.4% from CNY 341,280,060.27 in the previous period[20]. - Net profit for the current period is CNY 148,335,221.24, down 4.9% from CNY 155,353,043.36 in the previous period[22]. - Basic and diluted earnings per share are both CNY 0.82, compared to CNY 0.86 in the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥989,208,759.06, showing a slight increase of 0.23% from the end of the previous year[5]. - Total current assets amount to ¥721,786,720.43, a slight increase from ¥710,006,315.27 at the beginning of the year[18]. - Total assets as of September 30, 2023, are ¥989,208,759.06, compared to ¥986,904,775.50 at the start of the year[18]. - Total liabilities decreased to CNY 83,765,746.17 from CNY 121,796,983.85, a significant reduction of 31.2%[21]. - Total equity attributable to shareholders increased to CNY 905,443,012.89 from CNY 865,107,791.65, reflecting a growth of 4.7%[21]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥126,718,336.00, down 14.65% year-on-year[5]. - The net cash flow from operating activities for Q3 2023 was ¥126,718,336, a decrease of 14.6% compared to ¥148,460,770 in Q3 2022[25]. - The net cash flow from investment activities was ¥43,702,376, a significant improvement from a negative cash flow of ¥94,645,779 in the same period last year[25]. - Total cash and cash equivalents at the end of Q3 2023 reached ¥119,466,335, up from ¥60,863,346 at the end of Q3 2022, representing a 96.2% increase[25]. - Cash inflow from investment activities totaled ¥938,931,632, down from ¥1,145,681,713 in Q3 2022, indicating a decrease of 18.1%[25]. - Cash outflow for investment activities was ¥895,229,255.97, a decrease of 27.8% from ¥1,240,327,493.39 in Q3 2022[25]. Expenses - Cash paid for purchasing goods and services decreased by 48.20% to ¥16,387,252.88, mainly due to the termination of the implant agency business[9]. - Research and development expenses increased to CNY 33,278,022.33, up from CNY 26,487,387.87, indicating a growth of 25.6%[21]. - Sales expenses decreased to CNY 82,813,123.71 from CNY 89,573,104.96, a reduction of 7.5%[21]. - Cash paid for employee compensation in Q3 2023 was ¥62,499,190, slightly up from ¥62,002,846 in Q3 2022[25]. - Cash paid for taxes in Q3 2023 increased to ¥34,706,041, compared to ¥21,353,528 in Q3 2022, reflecting a 62.5% rise[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 16.353 million[12]. - The largest shareholder, Mibohai, holds 33.87% of shares, totaling 60,961,500 shares[12]. Regulatory and Product Development - The company received a medical device registration acceptance notice for its biological repair membrane on July 26, 2023[14]. - The company obtained a medical device registration certificate for its phosphoric acid etchant on August 23, 2023[14]. - The company announced the acceptance of its application for a dental fissure sealant on September 7, 2023[14]. - The company completed a product technical requirement change for its skin repair membrane on September 19, 2023[15]. Audit and Reporting - The company did not undergo an audit for the Q3 2023 report[26]. - The report was released by the board of directors on October 24, 2023[27].